GENEOPTIMIZER
LIVE

Serial Number

78274936

Owner

Geneart GmbH

Attorney

Kenya L. Williams

Filing Date

Jul 16, 2003

Add to watchlist:

No watchlists yet
View on USPTO

GENEOPTIMIZER Trademark

Serial Number: 78274936 • Registration: 3111123

GENEOPTIMIZER is a trademark filed by Geneart GmbH on July 16, 2003. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Geneart GmbH (5 trademarks)

Josef-Engert-Str. 9
D-93053 Regensburg , DE

Entity Type: 03

THERMO FISHER SCIENTIFIC GENEART GMBH (4 trademarks)

SANTA CLARA, CA 95051

Entity Type: 16

Geneart AG (7 trademarks)

Josef-Engert-Str. 11
Regensburg 93053 , DE

Entity Type: 03

Trademark Details

Filing Date

July 16, 2003

Registration Date

July 4, 2006

Published for Opposition

April 11, 2006

Goods & Services

[ Computer terminals; ] computer programs for use as tools in the field of biotechnology and molecular biology; computer software to increase potency of enzymes and enzyme preparations, bacteria preparations, bacteriological preparations, micro-organism cultures, biological preparations, diagnostic preparations; [ computer operating programs; computer peripheral devices; computer keyboards; blank magnetic data carriers; blank optical disks; data processors; computer memories; blank floppy disks; hard drives for computers; printers for use with computers; computer interfaces; laptop computers; data processing equipment, namely, readers and scanners; computer mouse; semiconductors; computer modems; computer monitors; computer hardware; notebook computers; ] automatic machines for the synthesis of deoxyribonucleic acids; and robotic machines for laboratory purposes

[ Medicines for human medical purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes, for use in the treatment of cancer, diabetes, Alzheimer's disease and infectious diseases; medicines for dental purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes, for use in the treatment of cancer, diabetes, Alzheimer's disease and infectious diseases; medicines for veterinary purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes, for use in the treatment of cancer, diabetes, Alzheimer's disease and infectious diseases; bacteriological preparations for medical and veterinary purposes, for use in the treatment of cancer, high blood pressure, diarrhea, skin irritations, infections, diabetes, autoimmune diseases and arthritis, as well as for use in gene therapy; biological preparations for medical purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes, for use in the treatment of cancer, diabetes, Alzheimer's disease and infectious diseases; biological preparations for veterinary purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones, and enzymes for use in the treatment of cancer, diabetes, Alzheimer's disease and infectious diseases; germicides for medical and laboratory equipment, institutional use, and domestic uses; vermicides for medical and laboratory equipment, institutional use, domestic use, and residential uses; fungicides for medical and laboratory equipment, institutional use, and domestic uses; biological and diagnostic materials and preparations for clinical and medical laboratory use, namely, proteins, DNA, RNA and modifications thereof ]

[ Bacteria for use in food manufacture, waste water treatment, fermentation, pharmaceutical research, manufacture of cosmetics, manufacture of scientific compounds, and manufacture of pharmaceutical compounds; bacteriological preparations for use in food manufacture, waste water treatment, fermentation, pharmaceutical research, manufacture of cosmetics, manufacture of scientific compounds, and manufacture of pharmaceutical compounds; micro-organism cultures for use in food manufacture, waste water treatment, fermentation, pharmaceutical research, manufacture of cosmetics, manufacture of scientific compounds, and manufacture of pharmaceutical compounds; biochemical catalysts for use in food manufacture, waste water treatment, fermentation, pharmaceutical research, manufacture of cosmetics, manufacture of scientific compounds, and manufacture of pharmaceutical compounds; biological and diagnostic materials and preparations for research use, namely, proteins, DNA, RNA and modifications thereof; and enzymes and enzyme preparations for use in the field of food manufacture, waste water treatment, fermentation, pharmaceutical research, manufacture of cosmetics, manufacture of scientific compounds, and manufacture of pharmaceutical compounds ]

Computer services, namely, updating of computer software for others, consulting in the field of biotechnology, designing computer software for others, maintenance of computer software for others, leasing of computer software; computer programming for others, leasing of computers, and reconstruction of computer data for others; chemical analysis for others; research for others in the fields of bacteriology, biology, chemistry, physics, genealogy, cosmetics, engineering, and machine engineering; laboratory services for others in the fields of bacteriology and chemistry; consultation in the fields of bacteriology, biology, chemistry, physics, genealogy, cosmetics, engineering and machine engineering; consultation pertaining to pharmacology; measuring calibration for others; development and research of new products for others; technical consultation in the field of environmental protection; technical project planning and consulting services in the fields of bacteriology, biology, chemistry, physics, genealogy, cosmetics, engineering, and machine engineering; and quality control for others

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jul 4, 2025 REM2
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 10, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 10, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 10, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 10, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 10, 2023 COAR
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Jun 14, 2016 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jun 14, 2016 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Jun 14, 2016 89AG
TEAS SECTION 8 & 9 RECEIVED
Jun 13, 2016 E89R
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 2, 2016 ASGN
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jul 4, 2015 REM2
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 23, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 23, 2014 REAP
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Aug 10, 2012 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Aug 10, 2012 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 10, 2012 APRE
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Jul 23, 2012 815F
TEAS SECTION 8 & 15 RECEIVED
Jul 23, 2012 E815
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 23, 2012 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 21, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 21, 2011 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 2, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 2, 2011 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 1, 2011 TCCA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 20, 2006 ASGN
REGISTERED-PRINCIPAL REGISTER
Jul 4, 2006 R.PR
PUBLISHED FOR OPPOSITION
Apr 11, 2006 PUBO
NOTICE OF PUBLICATION
Mar 22, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 2, 2006 PREV
ASSIGNED TO LIE
Sep 23, 2005 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2005 CNSA
EXAMINERS AMENDMENT E-MAILED
Sep 19, 2005 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 19, 2005 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Sep 14, 2005 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Sep 12, 2005 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 23, 2005 PREV
ASSIGNED TO LIE
Aug 19, 2005 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 15, 2005 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 15, 2005 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 8, 2005 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 8, 2005 TROA
PRIORITY ACTION E-MAILED
Jul 8, 2005 GPRA
PRIORITY ACTION WRITTEN
Jul 8, 2005 CPRA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jul 6, 2005 ZZZX
WITHDRAWN BEFORE PUBLICATION
Jun 17, 2005 CWBP
ASSIGNED TO LIE
Sep 17, 2004 ALIE
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 7, 2004 PREV
ASSIGNED TO LIE
Sep 3, 2004 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 3, 2004 CNSA
Sec. 1(B) CLAIM DELETED
May 5, 2004 1.BD
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2004 CRFA
PAPER RECEIVED
May 5, 2004 MAIL
NON-FINAL ACTION E-MAILED
Jan 6, 2004 GNRT
ASSIGNED TO EXAMINER
Jan 5, 2004 DOCK